|
CAS Number |
Product Name |
|
2641451-44-5 |
(S)-3-Bromo-2-(1-methoxyethyl)pyridine |
|
2641451-73-0 |
Methyl (S)-3-(4-bromothiazol-2-yl)-2-((tert-butoxycarbonyl)amino)propanoate |
|
2641451-74-1 |
(S)-3-(2-Bromothiazol-4-yl)-2-((tert-butoxycarbonyl)amino)propanoic acid |
|
2940879-42-3 |
(S)-3-(1-Ethyl-2-(2-(1-methoxyethyl)-5-(4-methylpiperazin-1-yl)pyridin-3-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-3-yl)-2,2-dimethylpropan-1-ol |
Complete series coverage, one-stop procurement. Daraxonrasib synthesis involves the coordinated supply of multiple high-complexity intermediates. Cosperpharm can simultaneously provide the core intermediates listed above, helping customers streamline supply chain management and ensure batch-to-batch consistency and compatibility.
Strict quality control, regulatory compliance. Each intermediate undergoes HPLC purity verification, chiral purity testing, and structural confirmation. Each batch is accompanied by a Certificate of Analysis (COA). For regulatory filing needs, DMF-ready documentation packages and customized quality agreements are available upon request.
Flexible supply, global delivery. From gram-scale research samples to hundred-gram process development, and to kilogram-scale production needs, Cosperpharm can provide packaging specifications and delivery cycles matching your project stage.
Daraxonrasib (RMC-6236) is an oral, RAS(ON) multiselective, tri-complex inhibitor of guanosine triphosphate–bound mutant and wild-type RAS protein isoforms developed by Revolution Medicines. It acts as a molecular glue, using cyclophilin A (CypA) as a chaperone to form a tri-complex with RAS-GTP, thereby blocking RAS from activating RAF and inhibiting downstream MAPK signaling .
The compound is a macrocyclic molecule (bRo5) with the molecular formula C₄₄H₅₈N₈O₅S and a molecular weight of 811.05, containing five defined chiral centers . In the Phase 1/2 RMC-6236-001 trial (NCT05379985), daraxonrasib demonstrated objective responses in more than 30% of patients with previously treated RAS-mutant non-small cell lung cancer (NSCLC), with durable responses across dose levels .
To obtain quotations, samples, or technical data for the Daraxonrasib (RMC-6236) full series of intermediates, please contact the Cosperpharm sales and technical team. We will respond to your inquiry within 1 business day.
